Aristotle Capital Management LLC Has $24.13 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Aristotle Capital Management LLC reduced its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 7.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 195,938 shares of the specialty pharmaceutical company's stock after selling 16,753 shares during the period. Aristotle Capital Management LLC owned 0.32% of Jazz Pharmaceuticals worth $24,130,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in JAZZ. AXA S.A. bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth about $4,747,000. AQR Arbitrage LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $5,150,000. Darwin Global Management Ltd. bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $59,668,000. AdvisorShares Investments LLC lifted its holdings in Jazz Pharmaceuticals by 113.5% in the fourth quarter. AdvisorShares Investments LLC now owns 10,460 shares of the specialty pharmaceutical company's stock valued at $1,288,000 after buying an additional 5,560 shares during the period. Finally, Northern Trust Corp boosted its stake in Jazz Pharmaceuticals by 18.9% in the fourth quarter. Northern Trust Corp now owns 521,196 shares of the specialty pharmaceutical company's stock valued at $64,185,000 after acquiring an additional 82,817 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Stock Down 1.5 %

NASDAQ JAZZ traded down $1.86 during trading on Monday, hitting $118.19. The stock had a trading volume of 1,276,961 shares, compared to its average volume of 806,697. Jazz Pharmaceuticals plc has a 12 month low of $95.49 and a 12 month high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company's 50-day moving average price is $122.63 and its two-hundred day moving average price is $122.52. The company has a market capitalization of $7.28 billion, a PE ratio of 16.65, a P/E/G ratio of 1.04 and a beta of 0.42.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now directly owns 33,318 shares in the company, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bruce C. Cozadd sold 6,500 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total value of $937,625.00. Following the sale, the chief executive officer now owns 464,058 shares in the company, valued at approximately $66,940,366.50. This represents a 1.38 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,236 shares of company stock worth $3,956,190. Insiders own 4.20% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on JAZZ. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their target price for the company from $145.00 to $179.00 in a research report on Friday, March 7th. Barclays reiterated an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Royal Bank of Canada reduced their target price on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Piper Sandler reaffirmed an "overweight" rating and issued a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $130.00 to $170.00 in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.